Celcuity, Inc. (NASDAQ:CELC) Receives $155.18 Consensus Target Price from Brokerages

Celcuity, Inc. (NASDAQ:CELC) has earned a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation and eleven have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $155.1818.

CELC has been the topic of several research reports. Weiss Ratings upgraded Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Stifel Nicolaus set a $150.00 target price on Celcuity in a report on Monday, May 4th. Guggenheim reissued a “buy” rating on shares of Celcuity in a research report on Wednesday, June 3rd. Craig Hallum restated a “buy” rating and set a $178.00 price target on shares of Celcuity in a research note on Wednesday, July 15th. Finally, Needham & Company LLC restated a “buy” rating and set a $157.00 price target on shares of Celcuity in a research note on Friday, May 15th.

Celcuity Price Performance

Shares of CELC stock opened at $82.62 on Friday. The company has a market capitalization of $4.03 billion, a P/E ratio of -21.18 and a beta of 0.16. The company’s 50-day simple moving average is $104.04 and its two-hundred day simple moving average is $110.37. Celcuity has a one year low of $13.59 and a one year high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.10. As a group, equities analysts anticipate that Celcuity will post -3.76 EPS for the current year.

Insider Activity

In other Celcuity news, Director Richard E. Buller sold 9,000 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at $949,509.60. This represents a 57.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director directly owned 65,000 shares in the company, valued at $9,144,200. This trade represents a 27.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Celcuity

Institutional investors have recently bought and sold shares of the business. Tudor Investment Corp ET AL purchased a new position in shares of Celcuity in the 3rd quarter valued at $1,351,000. Jennison Associates LLC purchased a new stake in shares of Celcuity during the 4th quarter worth $22,911,000. Hsbc Holdings PLC bought a new stake in Celcuity during the fourth quarter valued at about $1,058,000. Geode Capital Management LLC boosted its position in Celcuity by 8.4% during the fourth quarter. Geode Capital Management LLC now owns 830,684 shares of the company’s stock valued at $82,872,000 after purchasing an additional 64,213 shares in the last quarter. Finally, TD Asset Management Inc grew its stake in Celcuity by 34.0% in the fourth quarter. TD Asset Management Inc now owns 97,526 shares of the company’s stock valued at $9,727,000 after purchasing an additional 24,730 shares during the last quarter. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.